405 related articles for article (PubMed ID: 22806692)
1. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty.
Pollock J; Ho SV; Farid SS
Biotechnol Bioeng; 2013 Jan; 110(1):206-19. PubMed ID: 22806692
[TBL] [Abstract][Full Text] [Related]
2. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty.
Lim AC; Washbrook J; Titchener-Hooker NJ; Farid SS
Biotechnol Bioeng; 2006 Mar; 93(4):687-97. PubMed ID: 16259001
[TBL] [Abstract][Full Text] [Related]
3. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.
Pollock J; Coffman J; Ho SV; Farid SS
Biotechnol Prog; 2017 Jul; 33(4):854-866. PubMed ID: 28480535
[TBL] [Abstract][Full Text] [Related]
4. Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes.
Vermasvuori R; Hurme M
Biotechnol Prog; 2011; 27(6):1588-98. PubMed ID: 21954092
[TBL] [Abstract][Full Text] [Related]
5. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty.
Lim AC; Zhou Y; Washbrook J; Sinclair A; Fish B; Francis R; Titchener-Hooker NJ; Farid SS
Biotechnol Prog; 2005; 21(4):1231-42. PubMed ID: 16080707
[TBL] [Abstract][Full Text] [Related]
6. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
[TBL] [Abstract][Full Text] [Related]
7. Bioreactor productivity and media cost comparison for different intensified cell culture processes.
Xu S; Gavin J; Jiang R; Chen H
Biotechnol Prog; 2017 Jul; 33(4):867-878. PubMed ID: 27977910
[TBL] [Abstract][Full Text] [Related]
8. Data mining for rapid prediction of facility fit and debottlenecking of biomanufacturing facilities.
Yang Y; Farid SS; Thornhill NF
J Biotechnol; 2014 Jun; 179():17-25. PubMed ID: 24637375
[TBL] [Abstract][Full Text] [Related]
9. Decisional tool to assess current and future process robustness in an antibody purification facility.
Stonier A; Simaria AS; Smith M; Farid SS
Biotechnol Prog; 2012 Jul; 28(4):1019-28. PubMed ID: 22641562
[TBL] [Abstract][Full Text] [Related]
10. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
Yang WC; Lu J; Kwiatkowski C; Yuan H; Kshirsagar R; Ryll T; Huang YM
Biotechnol Prog; 2014; 30(3):616-25. PubMed ID: 24574326
[TBL] [Abstract][Full Text] [Related]
11. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
[TBL] [Abstract][Full Text] [Related]
12. Process intensification to produce a difficult-to-express therapeutic enzyme by high cell density perfusion or enhanced fed-batch.
Särnlund S; Jiang Y; Chotteau V
Biotechnol Bioeng; 2021 Sep; 118(9):3533-3544. PubMed ID: 33914903
[TBL] [Abstract][Full Text] [Related]
13. Integrated continuous production of recombinant therapeutic proteins.
Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
[TBL] [Abstract][Full Text] [Related]
14. High cell density fed batch and perfusion processes for stable non-viral expression of secreted alkaline phosphatase (SEAP) using insect cells: comparison to a batch Sf-9-BEV system.
Jardin BA; Montes J; Lanthier S; Tran R; Elias C
Biotechnol Bioeng; 2007 Jun; 97(2):332-45. PubMed ID: 17054119
[TBL] [Abstract][Full Text] [Related]
15. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
[TBL] [Abstract][Full Text] [Related]
16. Automated dynamic fed-batch process and media optimization for high productivity cell culture process development.
Lu F; Toh PC; Burnett I; Li F; Hudson T; Amanullah A; Li J
Biotechnol Bioeng; 2013 Jan; 110(1):191-205. PubMed ID: 22767053
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein 27 overexpression in CHO cells modulates apoptosis pathways and delays activation of caspases to improve recombinant monoclonal antibody titre in fed-batch bioreactors.
Tan JG; Lee YY; Wang T; Yap MG; Tan TW; Ng SK
Biotechnol J; 2015 May; 10(5):790-800. PubMed ID: 25740626
[TBL] [Abstract][Full Text] [Related]
18. Developing an ultra-intensified fed-batch cell culture process with greatly improved performance and productivity.
Xiang S; Zhang J; Yu L; Tian J; Tang W; Tang H; Xu K; Wang X; Cui Y; Ren K; Cao W; Su Y; Zhou W
Biotechnol Bioeng; 2024 Feb; 121(2):696-709. PubMed ID: 37994547
[TBL] [Abstract][Full Text] [Related]
19. Orbitally Shaken Single-Use Bioreactor for Animal Cell Cultivation: Fed-Batch and Perfusion Mode.
Bürgin T; Coronel J; Hagens G; Keebler MV; Genzel Y; Reichl U; Anderlei T
Methods Mol Biol; 2020; 2095():105-123. PubMed ID: 31858465
[TBL] [Abstract][Full Text] [Related]
20. Cell-controlled hybrid perfusion fed-batch CHO cell process provides significant productivity improvement over conventional fed-batch cultures.
Hiller GW; Ovalle AM; Gagnon MP; Curran ML; Wang W
Biotechnol Bioeng; 2017 Jul; 114(7):1438-1447. PubMed ID: 28128436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
